Equistone Partners has sold their majority stake in OTTO Life Science Engineering to SPIE Group, enhancing SPIE's capabilities in the pharmaceutical and biotech sectors.

Information on the Target

OTTO Life Science Engineering GmbH (OTTO LSE) is a prominent provider of Engineering, Procurement, and Construction (EPC) services specifically tailored for pharmaceutical and biotechnology production facilities and laboratories. Established as a key player in the EPC sector, the company specializes in delivering comprehensive turnkey solutions that encompass the entire value chain, including planning, designing, constructing, and re-qualifying facilities. As of 2023, OTTO LSE has achieved annual sales of approximately €75 million and employs 140 skilled professionals who serve a distinguished international clientele.

Headquartered in Nuremberg, OTTO LSE also operates five additional locations throughout Germany, focusing on areas such as process design, cleanroom technology, and building services. The company’s strong reputation and expertise in the pharmaceutical and biotech industries position it for continued growth and innovation as part of SPIE Group.

Industry Overview in Germany

The pharmaceutical and biotechnology sectors in Germany are among the most advanced in Europe, with the country being home to a robust network of companies engaged in drug development, production, and related services. Germany has consistently been a leader in life